The year of the mega-merger continues with Merck & Co’s move to buy Schering-Plough for $41.1bn, with the intention of boosting its pipeline, entering new markets and creating a “powerful biologics presence”.
The US Food and Drug Administration (FDA) has sent Merck & Co a
warning letter saying it has failed to correct a number of
manufacturing deficiencies at its main vaccine manufacturing plant
in West Point, Pennsylvania.
Merck Serono intends to forge ahead with severing its investment in
diabetes and either sell or partner out its existing research and
development (R&D) activities in this field, which it no longer
feels able to compete in effectively.
Germany's Merck has announced its biggest investment in
pharmaceuticals in its 338-year-old history, as its top-selling
oncology drug Erbitux (cetuximab) has driven the company to
allocate €190m for the construction of its first...
For the first time Merck has opened the doors of its
under-construction manufacturing plant in North Carolina to public
officials, boasting it will eventually contribute about two-thirds
of its annual live-virus vaccine production.
Newly-approved pearlescent pigments that can produce sparkly
metallic, satiny and shimmery finishes on drug coatings could be
used as one additional step in the fight against counterfeiting,
say its developers, EMD Chemicals - part...
Pennsylvania environmental regulators have accused Merck of
hampering their investigation of a chemical discharge from its West
Point facility that resulted in a major fish kill on the local
creek and threatened the water supplies...
In an incident that state and federal environmental regulators are
treating as "serious," Merck released 25 gallons of a
cyanide-containing chemical from its West Point facility in
Pennsylvania to the sewer, killing hundreds...
Drug giant Merck & Co has seen flat sales and a rise in
operating costs in the first quarter of 2006, as its restructuring
initiative, which contract manufacturers welcomed, takes its toll
on the company.
Merck & Co said it would cut an additional $1 billion (€832
million) through 2010 as it struggles to regain R&D momentum
after mounting lawsuits, generic competition and falling revenue
and profit threaten to engulf the company,...
Merck is to cut 7,000 jobs, close five factories and three research
facilities, as the US pharmaceutical company continues to suffer
from the devastating repercussions caused by its painkiller Vioxx
and the pending lawsuits.
Merck has signed a research and drug development agreement with
FoxHollow Technologies, which represents the first
pharmaceutical-medical device partnership aimed at identifying
cardiovascular biomarkers for use as diagnostics and...
The news that the widow of a man who died after taking Vioxx was
awarded $253.4 million has opened up the possibility of US lawsuits
filed by patients worldwide, who were prescribed the drug that was
linked to an increase in heart...
The Supreme Court's decision to allow drug companies to receive
exemptions from patent infringement during key early-stage research
carries wider significance throughout the industry as it reduces
licence negotiation for patented...
Merck KGaA announced its intention to relocate its pharmaceutical
research operations in Scotland to its larger biotech research
facility in the United States, withdrawing its DeImmunisation
technology service at the same time.
The US Supreme Court's decision as to how much a patent can
restrict research conducted by another company is a question that
is certain to affect the way innovative new drugs are researched
The bad press surrounding the pharmaceutical industry continues
with claims that Merck & Co executives were concerned about
infant exposure to mercury in vaccines several years before the US
Food and Drug Administration made the...
Merck & Co, still reeling from the impact of pulling its
painkiller Vioxx (rofecoxib) from the market, is to slash its staff
by 5,100 positions in a bid to save hundreds of millions of dollars
by the end of the year.
BASF and Merck KGaA have joined DSM in reporting encouraging
first-quarter 2004 results, raising hopes further that the European
chemicals sector may be about to move into recovery mode, writes
Germany's KGaA has announced plans to sell off its laboratory
distribution business VWR International and operate as a smaller,
higher-margin business focused on pharmaceuticals, chemicals and
The European Commission has given the go-ahead for Germany to grant
a proposed €78 million in aid to help Merck KGaA build a new
biopharmaceuticals plant for the production of oncology products in